Humacyte's products developed from its core technology

Humacyte, a privately held company, is primarily focused on developing products for vascular disease and for therapeutic filling and soft tissue repair. The company uses its innovative and proprietary platform technology to engineer human, extracellular matrix-based tissues that can be shaped into tubes, sheets, or particulate conformations, with properties similar to native tissues. Incorporated in late 2004, Humacyte licensed technology from MIT and Duke University. Since then, Humacyte has made considerable progress in the development of its human-based matrix products which can be used in a number of specific applications, with the potential to significantly improve treatment outcomes for a variety of patients. To date, Humacyte has attained proof of concept in several different models and is preparing for pivotal clinical studies. The company's process uses a unique cell source, and its proprietary technologies are designed to result in off-the-shelf products that can be utilized in any patient.

Proof of Concept
Humacyte has successfully performed proof of concept studies demonstrating the technology's ability to be manufactured and implanted as a vascular replacement. Other pivotal proof of concept studies are underway.

Product Pipeline
Humacyte is developing its technology for multiple product opportunities. Markets to be addressed include: cardiovascular, soft tissue reconstruction, neurosurgical, and orthopaedic.